Compugen (NASDAQ:CGEN – Get Free Report) and Onconetix (NASDAQ:ONCO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.
Volatility & Risk
Compugen has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500.
Valuation and Earnings
This table compares Compugen and Onconetix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compugen | $72.76 million | 2.57 | $35.34 million | $0.38 | 5.21 |
| Onconetix | $645,824.00 | 0.51 | -$14.03 million | $248.12 | 0.00 |
Compugen has higher revenue and earnings than Onconetix. Onconetix is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for Compugen and Onconetix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compugen | 0 | 1 | 3 | 1 | 3.00 |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
Compugen presently has a consensus price target of $5.00, suggesting a potential upside of 152.53%. Given Compugen’s stronger consensus rating and higher possible upside, equities analysts clearly believe Compugen is more favorable than Onconetix.
Institutional & Insider Ownership
12.2% of Compugen shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Compugen and Onconetix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compugen | 47.56% | 42.57% | 26.13% |
| Onconetix | -1,575.89% | -91.95% | -53.76% |
Summary
Compugen beats Onconetix on 13 of the 15 factors compared between the two stocks.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
